What is the current stock price of Kodiak Sciences Inc. (KOD)?

As of the latest market data, Kodiak Sciences Inc. (KOD) is trading at $43.11. The stock has seen a gain of 1.77% today.

Does Kodiak Sciences Inc. (KOD) pay a dividend?

Based on current data, Kodiak Sciences Inc. does not have a confirmed active dividend policy.

What is the market cap of Kodiak Sciences Inc.?

The current market capitalization of Kodiak Sciences Inc. (KOD) is approximately unavailable.

KOD

Kodiak Sciences Inc.·Healthcare

43.11

1.771%(+0.75)

Market Closed

43.99

2.041%(+0.88)

After Hours

Last Updated: — ET

52W L: $2.1052W H: $45.60

KOD NEWS

zacks.com

Apr 1

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.

prnewswire.com

Mar 31

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.

forbes.com

Mar 30

Kodiak Sciences: Road To $120

Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fueled by robust Phase 3 GLOW2 results for Zenkuda (tarcocimab), an experimental treatment aimed at retinal vascular disorders.

defenseworld.net

Mar 28

Kodiak Sciences (NASDAQ:KOD) Reaches New 52-Week High – Time to Buy?

Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shares hit a new 52-week high during trading on Thursday. The company traded as high as $36.84 and last traded at $36.0160, with a volume of 3075248 shares. The stock had previously closed at $22.75. More Kodiak Sciences News Here are the key news stories impacting

zacks.com

Mar 27

KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate

Kodiak Sciences rallies 75% as phase III GLOW2 data show Zenkuda's strong efficacy, safety and risk reduction in diabetic retinopathy patients.

benzinga.com

Mar 27

Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

Investors appear to be responding to both the strength of the data and the possibility of a faster path toward a biologics license application, or BLA. Here's what investors need to know.

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Sector

Healthcare

Industry

Biotechnology

Employees

109

IPO Date

2018-10-04

Beta

2.40

Websitekodiak.com↗